Expansion Opportunity SBH Sciences is a mid-sized preclinical CRO with a broad cytokine and biomarker assay portfolio and recent activity in hepatocyte-derived extracellular vesicles for NAFLD/NASH, indicating potential demand for in vivo modeling, biomarker discovery, and advanced RNA/protein analysis services.

Clinical Development Readiness With over 27 years serving 300+ biotech and diagnostic clients and a track record of on-time delivery, SBH Sciences presents a reliable partner for early-stage companies seeking incubator-model support, lead discovery screening, and comprehensive analytical workups to de-risk programs before IND filing.

High-Value Assay Library Access to the largest US cytokine bioassay collection and extensive cytotoxicity, biomarker measurement, functional activity testing, and kinase screening capabilities offers repeatable, scalable services that can be bundled to accelerate oncology and inflammation programs.

Strategic Fit for NAFLD/NASH Recent hepatocyte-isolated extracellular vesicle platform development focused on RNA and protein biomarkers for NAFLD/NASH suggests SBH Sciences could partner on biomarker-driven trials or companion diagnostics, aligning with pharma companies pursuing liver disease therapies.

Revenue Diversification Current revenue range indicates a growing but still agile operation with room to scale; potential sales opportunities include expanding in vivo modeling, ELISA and Luminex platforms, and multiplexed analytics contracts with mid-to-large biotech and diagnostic firms seeking robust CRO partners.